372 related articles for article (PubMed ID: 8242228)
1. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
2. Reduction in the number of thromboxane receptors on human platelets after exposure to GR32191.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):548-52. PubMed ID: 8242229
[TBL] [Abstract][Full Text] [Related]
3. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
4. Selective modulation of the human platelet thromboxane A2/prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solubilized platelet membranes.
Parent CA; Lagarde M; Venton DL; Le Breton GC
J Biol Chem; 1992 Apr; 267(10):6541-7. PubMed ID: 1532390
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
6. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
8. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
9. Characterization and localization of thromboxane A2 receptor in human and guinea-pig nasal mucosa using radiolabelled (+)-S-145.
Arimura A; Miwa M; Hasegawa H; Kishino J; Notoya M; Yasui K; Komori M; Iwata S
Br J Pharmacol; 1998 Jun; 124(4):795-803. PubMed ID: 9690873
[TBL] [Abstract][Full Text] [Related]
10. Characterization of platelet thromboxane A2/prostaglandin H2 receptor by a novel thromboxane receptor antagonist, [3H]S-145.
Hanasaki K; Nagasaki T; Arita H
Biochem Pharmacol; 1989 Jun; 38(12):2007-17. PubMed ID: 2525906
[TBL] [Abstract][Full Text] [Related]
11. Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets.
Hedberg A; Hall SE; Ogletree ML; Harris DN; Liu EC
J Pharmacol Exp Ther; 1988 Jun; 245(3):786-92. PubMed ID: 2968449
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
13. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems.
Takahara K; Murray R; FitzGerald GA; Fitzgerald DJ
J Biol Chem; 1990 Apr; 265(12):6836-44. PubMed ID: 2139029
[TBL] [Abstract][Full Text] [Related]
14. Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets.
Liel N; Mais DE; Halushka PV
Prostaglandins; 1987 Jun; 33(6):789-97. PubMed ID: 2959986
[TBL] [Abstract][Full Text] [Related]
15. Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes.
Theis JG; Dellweg H; Perzborn E; Gross R
Biochem Pharmacol; 1992 Aug; 44(3):495-503. PubMed ID: 1387312
[TBL] [Abstract][Full Text] [Related]
16. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548).
Kattelman EJ; Venton DL; Le Breton GC
Thromb Res; 1986 Feb; 41(4):471-81. PubMed ID: 3008368
[TBL] [Abstract][Full Text] [Related]
17. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors.
Liu EC; Hedberg A; Goldenberg HJ; Harris DN; Webb ML
Prostaglandins; 1992 Aug; 44(2):89-99. PubMed ID: 1438880
[TBL] [Abstract][Full Text] [Related]
18. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
Thomas M; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
[TBL] [Abstract][Full Text] [Related]
19. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
20. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
Turini ME; Holub BJ
Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
